Alcohol dose in septal ablation for hypertrophic obstructive
cardiomyopathy

J 2021

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

VESELKA, Josef; Lothar FABER; Max LIEBREGTS; Robert COOPER; Jaroslav JANUSKA et. al.

Basic information

Original name

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

Authors

VESELKA, Josef (203 Czech Republic, guarantor); Lothar FABER; Max LIEBREGTS; Robert COOPER; Jaroslav JANUSKA (203 Czech Republic); Maksim KASHTANOV; Maciej DABROWSKI; Peter Riis HANSEN; Hubert SEGGEWISS; Jiri BONAVENTURA (203 Czech Republic); Eva POLAKOVA (203 Czech Republic); Eva HANSVENCLOVA (203 Czech Republic); Henning BUNDGAARD; Jurrien TEN BERG; Rodney Hilton STABLES; Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Morten Kvistholm JENSEN

Edition

International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2021, 0167-5273

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 4.039

RIV identification code

RIV/00216224:14110/21:00123837

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.ijcard.2021.02.056

UT WoS

000730511500028

EID Scopus

2-s2.0-85102641313

Keywords in English

Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose

Abstract

V originále

Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.

Cite

VESELKA, Josef; Lothar FABER; Max LIEBREGTS; Robert COOPER; Jaroslav JANUSKA; Maksim KASHTANOV; Maciej DABROWSKI; Peter Riis HANSEN; Hubert SEGGEWISS; Jiri BONAVENTURA; Eva POLAKOVA; Eva HANSVENCLOVA; Henning BUNDGAARD; Jurrien TEN BERG; Rodney Hilton STABLES; Jiří JARKOVSKÝ and Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology. Clare: Elsevier Ireland Ltd., 2021, vol. 333, June 2021, p. 127-132. ISSN 0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.

@article{1823829,
   author = {Veselka, Josef and Faber, Lothar and Liebregts, Max and Cooper, Robert and Januska, Jaroslav and Kashtanov, Maksim and Dabrowski, Maciej and Hansen, Peter Riis and Seggewiss, Hubert and Bonaventura, Jiri and Polakova, Eva and Hansvenclova, Eva and Bundgaard, Henning and ten Berg, Jurrien and Stables, Rodney Hilton and Jarkovský, Jiří and Jensen, Morten Kvistholm},
   article_location = {Clare},
   article_number = {June 2021},
   doi = {http://dx.doi.org/10.1016/j.ijcard.2021.02.056},
   keywords = {Alcohol septal ablation; Hypertrophic cardiomyopathy; Alcohol dose},
   language = {eng},
   issn = {0167-5273},
   journal = {International Journal of Cardiology},
   title = {Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy},
   url = {https://www.sciencedirect.com/science/article/pii/S016752732100365X?via%3Dihub#!},
   volume = {333},
   year = {2021}
}

TY  - JOUR
ID  - 1823829
AU  - Veselka, Josef - Faber, Lothar - Liebregts, Max - Cooper, Robert - Januska, Jaroslav - Kashtanov, Maksim - Dabrowski, Maciej - Hansen, Peter Riis - Seggewiss, Hubert - Bonaventura, Jiri - Polakova, Eva - Hansvenclova, Eva - Bundgaard, Henning - ten Berg, Jurrien - Stables, Rodney Hilton - Jarkovský, Jiří - Jensen, Morten Kvistholm
PY  - 2021
TI  - Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy
JF  - International Journal of Cardiology
VL  - 333
IS  - June 2021
SP  - 127-132
EP  - 127-132
PB  - Elsevier Ireland Ltd.
SN  - 01675273
KW  - Alcohol septal ablation
KW  - Hypertrophic cardiomyopathy
KW  - Alcohol dose
UR  - https://www.sciencedirect.com/science/article/pii/S016752732100365X?via%3Dihub#!
N2  - Background: The aim of this study was to evaluate short-and long-term outcomes related to dose of alcohol administered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM). Current guidelines recommend using 1-3 mL of alcohol administered in the target septal perforator artery, but this recommendation is based more on practical experience of interventionalists rather than on systematic evidence. Methods: We included 1448 patients and used propensity score to match patients who received a low-dose (1.0-1.9 mL) versus a high-dose (2.0-3.8 mL) of alcohol during ASA. Results: The matched cohort analysis comprised 770 patients (n = 385 in both groups). There was a similar occurrence of 30-day post-procedural adverse events (13% vs. 12%; p = 0.59), and similar all-cause mortality rates (0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up (5.4 +/- 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient years in the low dose and the high dose group (logrank, p = 0.92), respectively. There were no significant differences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04). Conclusions: Matched HOCM patients undergoing ASA with a low-dose (1.0-1.9 mL) or a high-dose (2.0-3.8 mL) of alcohol had similar short-and long-term outcomes. A higher rate of repeated septal reduction procedures was observed in the group treated with a low-dose of alcohol.
ER  -

VESELKA, Josef; Lothar FABER; Max LIEBREGTS; Robert COOPER; Jaroslav JANUSKA; Maksim KASHTANOV; Maciej DABROWSKI; Peter Riis HANSEN; Hubert SEGGEWISS; Jiri BONAVENTURA; Eva POLAKOVA; Eva HANSVENCLOVA; Henning BUNDGAARD; Jurrien TEN BERG; Rodney Hilton STABLES; Jiří JARKOVSKÝ and Morten Kvistholm JENSEN. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. \textit{International Journal of Cardiology}. Clare: Elsevier Ireland Ltd., 2021, vol.~333, June 2021, p.~127-132. ISSN~0167-5273. Available from: https://dx.doi.org/10.1016/j.ijcard.2021.02.056.

Přehled o publikaci